St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Also called: NF-1, NF1, von Recklinghausen syndrome
Neurofibromatosis type 1 (NF1) is a rare genetic disorder that can be passed down from parents to their children (inherited). People with NF1 have a higher risk of developing certain kinds of tumors. These tumors are usually non-cancerous (benign) but may sometimes be cancerous (malignant).
NF1 can affect many areas of the body. The severity of the condition and the body areas affected can vary.
Nearly all people with NF1 develop non-cancerous (benign) cutaneous (on the skin) neurofibromas. Cutaneous neurofibromas may look like bumps under the skin. They usually start to appear in late childhood and teenage years. They can continue to develop throughout life. Many women with NF1 experience a rapid increase in the number and size of cutaneous neurofibromas during pregnancy. These tumors are not cancerous, but may cause itching, occasional pain, and may alter a person’s physical appearance (disfigurement).
Other neurofibromas can grow in childhood and are called subcutaneous (under the skin) or plexiform neurofibromas. While these neurofibromas are not cancerous, they can become large. They may cause pain, nerve damage, or disfigurement.
Plexiform neurofibromas are usually present in young childhood. These tumors can cause pain, push on nearby organs, may affect movement, and alter a child’s appearance (disfigurement). They may first appear either under the skin or they could be deeper inside the body and seen on an imaging exam. These tumors occur in 30–50% of patients with NF1.
A plexiform neurofibroma has a small chance of becoming a cancer called a malignant peripheral nerve sheath tumor (MPNST) during adolescence and adulthood.
About 10% (1 in 10) of people with NF1 will develop an MPNST near a neurofibroma that is already present. It is easier to treat these tumors if they are diagnosed early.
The 2 most common central nervous system tumors in people with NF1 are optic gliomas and brain tumors. Optic gliomas may form on the optic nerve. This nerve connects the eye to the brain. About 20% (2 in 10) of children with NF1 develop optic gliomas, which usually start in childhood. Often, these tumors do not cause any symptoms, even into adulthood. Children with NF1 should be followed closely by an eye doctor in early childhood to monitor their vision closely.
Tumors may also form in other parts of the brain. About 3% of people with NF1 develop brain tumors (such as gliomas). Most often, these tumors do not cause symptoms and do not need any treatment, but patients with these tumors should be watched closely by a neuro-oncologist. Though less common, aggressive gliomas can develop in people with NF1.
Women with NF1 who are under age 50 have a higher risk of developing breast cancer than women without NF1. After age 50, the risk is the same for women with and without NF1.
People with NF1 have a higher risk of developing certain other cancers than those without the condition. But the overall risk is still very low. These cancers include:
NF1 can affect many areas of the body. Not all patients will have all of the following, even patients within the same family.
Health issue | Lifetime risks |
---|---|
Café au lait spots (smooth, dark, flat birthmarks) | 100% |
Freckles in the groin, underarms, and under the breasts | 90% |
Benign growths on the iris, the colored part of the eye (Lisch nodules) | 60% |
Learning disability | 50-75% |
Autism spectrum disorders | 30% |
Larger-than-expected head size | 25% |
Abnormal skeletal growth, including curved spine (scoliosis) and bowing of the legs | 15% |
High blood pressure (hypertension) and blood vessel disorders | 15% |
Heart defects | less than 2% |
Symptoms of NF1 vary from person to person even within a family. Some symptoms of NF1 are:
People with NF1 should watch closely for general symptoms that could signal a tumor, such as:
It is important to seek medical help if anything unusual appears.
Neurofibromatosis type 1(NF1) is caused by changes in the NF1gene that make it not work correctly. The NF1 gene carries information that helps control how and when cells grow, divide, and die.
Children without this disorder carry 2 normal copies of the NF1 gene in their cells. One copy is inherited from the child’s mother, and the other comes from the child’s father.
Children who do have neurofibromatosis type 1 inherit 1 normal copy of the NF1 gene and 1 copy that is changed (mutated). This NF1 mutation makes the gene not work correctly. As a result, it is harder for cells to control their growth and functions.
About 50% (1 in 2) of children with neurofibromatosis type 1 inherit the NF1 gene mutation from a parent who also has this disorder. The other 50% (1 in 2) of children with this disorder have a new NF1 mutation that did not come from a parent. These children have no history of this disorder in their family. In such cases, an NF1 gene mutation happened either in:
These children are the first in their families to have neurofibromatosis type 1.
Some children with a clinical diagnosis of NF1 may not have a mutation in NF1 in their blood cells, but they could be a “mosaic” of NF1. “Mosaic” means a mixture.
A child with mosaic neurofibromatosis type 1 inherits 2 normal copies of the NF1 gene. One copy is from the mother. The other copy is from the father. But early in development, before the person is born, 1 copy of the NF1 gene becomes mutated (changed) within 1 cell of the developing baby. That cell will keep growing and dividing, making many more cells like it in the baby’s body. All the cells that grow from that early cell have the mutated copy of the NF1 gene. Other cells that did not grow from the 1 mutated cell will have 2 normal copies of the NF2 gene. That is why it is called mosaic NF1; the child’s body is a mixture of normal cells and mutated cells.
With mosaic neurofibromatosis type 1, it is hard to know which cells have the NF1 mutation. In this case, it is not possible to predict the exact risk of passing the NF1 mutation on to future children. The risk is up to 50% (1 in 2) chance of passing the NF1 mutation onto each child.
Children with mosaic neurofibromatosis type 1 generally only have features of the condition in the areas of the body that contain the NF1 mutation.
A health care provider may suspect that your child has NF1 after studying their medical and family cancer history.
This information helps the health care provider and the genetic counselor know if:
Your doctor or genetic counselor may recommend NF1 genetic testing if they suspect NF1.
Learn more about types of genetic tests.
A blood sample is sent to a genetic testing lab. The lab runs a special type of genetic test, called next-generation sequencing, that looks for changes in the NF1 gene.
If your child has an NF1 mutation, a genetic counselor will work with your family to:
Genetic testing can detect a mutated NF1 gene in about 90–95% of people with a clinical diagnosis of NF1.
There may be other genes or types of mutations causing this condition that doctors do not yet know about. So, a person can still have NF1 even if no NF1 mutation is found.
People who are mosaic NF1 may not have a mutation in NF1 in their blood cells, but they could be a mosaic NF1. They could have mutated cells in another part of their body.
Parents may choose to do prenatal testing to find out if a pregnancy is affected with a known NF1 mutation.
You should work with a genetic counselor to review the pros and cons of the test. The genetic counselor can also help you prepare for the test results.
Testing before pregnancy is called preimplantation genetic testing (PGT). This special type of genetic testing is done along with in vitro fertilization (IVF). PGT tests embryos for a known NF1 mutation before a doctor places an embryo into the uterus.
Testing during pregnancy can help doctors see if a pregnancy has a known NF1 mutation. A doctor gathers cells from the pregnancy in 1 of 2 ways:
After tissue collection, the lab checks the sample for the NF1 mutation. Both tests carry minor risks. Discuss risks with an experienced health care provider or a genetic counselor.
Take time to think carefully about the benefits and risks of genetic testing. Speak with a genetic counselor before testing. If you decide to get tested, talk with your health care provider or a genetic counselor about your results so you can understand what they mean.
Sometimes, children or adults with NF1 feel sad, anxious, or angry after getting their test results. Parents may feel guilty if they pass the NF1 gene mutation to 1 or more of their children. People with the NF1 gene mutation may also have trouble getting disability or life insurance.
Read more about genetic discrimination.
It is possible to get a clinical diagnosis of NF1 without genetic testing. A person with 2 or more features can be diagnosed with NF1. These features are:
If a person has a negative genetic test but still has 2 or more of these features, they can still be diagnosed with NF1.
Monitoring and follow-up care for NF1 depend on how severe the disease is, the location of any tumors that may arise, and a person’s overall health.
Care may involve managing symptoms with medicines and surgery to remove any cancerous tissues or tumors. Care may also include other treatments such as chemotherapy to fight any cancers that may develop. Targeted medications known as MEK-inhibitors can act on specific types of NF1. This is a new way of treating many of these tumors with fewer side effects than chemotherapy.
Radiation treatment for NF1 patients should be avoided if possible.
Because NF1 is a complex condition, parents should discuss screening options for their child with an experienced doctor who knows this condition well. The goal of screening is to find and treat tumors early. Doing so allows the best outcome for patients. There are clinics throughout the country that specialize in taking care of people with NF1.
It is also important that parents also work with a genetic counselor to find experienced doctors for their child. To find a genetics counselor in your area, visit the Personalized Care for Your Genetic Health webpage.
Although most of the tumors related to NF1 are not cancerous, people with NF1 should be monitored for development of these tumors. Some non-cancerous tumors cause problems. Vision loss can occur from optic pathway gliomas. Neurofibromas may cause nerve damage. It is important to carefully monitor neurofibromas for signs they are becoming cancerous. Early screening and detection allow the best outcome for patients.
The following lifelong screenings are recommended for children with NF1:
As a child moves into adulthood, they may need more screenings for breast cancer and signs of a malignant peripheral nerve sheath tumor.
These recommendations may change over time as doctors learn more about NF1.
People of any age with NF1 have a higher risk of cancer than people without NF1. They should monitor their health and adopt healthy habits throughout life.
It is important to continue to have regular physical check-ups and screenings. That way, any cancer can be found early and at the most treatable stage.
Habits that will help you maintain a healthy lifestyle include:
The St. Jude Cancer Predisposition Program is dedicated to diagnosing and screening children with a genetic predisposition for cancer. Our program offers the best clinical care possible. We engage in cutting-edge research to gain more information about genetic disorders and cancer, and to improve the care and treatment for patients who are affected by these conditions. Learn more about the Division of Cancer Predisposition at St. Jude.
Our genetic counselors, clinicians, genetics nurse practitioners, and research assistants work together to provide patients with:
NF1 increases your child’s risk for tumors and, less commonly, certain cancers.
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults who have cancers associated with NF1.
Study goal:
To learn more about participants beliefs, attitudes, and questions about gene therapy to help make web-based resources to share information. This could help patients make treatment decisions.
Age:
18 to 35 years old with rare genetic diseases
Study goal:
The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.
Study goal:
To provide a high-quality repository of tumor and normal samples to facilitate translational research performed by St Jude faculty and their collaborators
Study goal:
1) Test each patient for hundreds of gene variations that might be important for drug use. All of the gene test results will be in the research laboratory, but as time goes on, the study will evaluate scientific evidence and selectively move test results for a few genes into the medical record if the evidence strongly shows that the result can help in better prescribing of drugs for patients; 2) Estimate how often pharmacogenetic test results are moved from research tests into a patient’s medical record; 3) Use methods to choose which of these tests should be put in the medical record; 4) Use computer-based tools in the electronic medical record to help doctors use gene test results when prescribing drugs; 5) Share feelings and concerns of patients and their families about gene test information being put in their medical record.
Study goal:
The main purpose of this trial is to learn about the genetic causes of cancer.
Age:
Younger than 50 years old
Study goal:
To collect data about how Friedreich’s ataxia progresses over time and affects the daily life of patients.
Age:
Any
Study goal:
To find out how much patients with hemophilia B, their caregivers, and health care workers know about gene therapy for this disease, and how they feel about gene therapy. This will help us better educate patients and caregivers about gene therapy for hemophilia B.
Age:
12 years and older
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334
If you have questions about the Genetic Predisposition Clinic and care for NF1, email our team at GPTeam@stjude.org.